Frankincense (Boswellia sacra)
What Is Frankincense?
Botanists and formularies know Frankincense as Boswellia sacra, a plant of the Burseraceae family, native to the dry hills of the Horn of Africa, Arabia and India. The material in circulation is resin (oleogum) — a resin, tapped from the living tree. Most people search for it simply as Frankincense; suppliers, pharmacopoeias and interaction databases list it as Boswellia sacra, and matching the two is the first step in identifying what is actually in a product. In the hand it reads as warm, balsamic, woody, slightly citrus — a practical marker of freshness and correct identification.
In African traditional medicine, Frankincense is a long-standing entry. Its use is carried largely through oral transmission among traditional healers, and it entered the written record comparatively late, through colonial-era botanical surveys and modern ethnobotanical fieldwork. Beyond its practical use it carries cultural associations — sacred incense of temples, churches, and mosques worldwide and used to consecrate sacred space and deepen prayer.
Today most searches for Frankincense come from people reading about anxiety, grounding, pain relief and joint health, or checking how it sits alongside a medication they already take. The use most often documented in the literature is boswellic acids inhibit 5-LOX — anti-inflammatory, followed by may reduce osteoarthritis pain in RCTs.
How Does Frankincense Work?
Frankincense works as a mixture rather than a single isolated compound, and its profile is usually described by the class of constituents present in resin (oleogum) rather than by one marker molecule.
African traditional practice situates a plant within community, season and preparation ritual as much as within its chemistry. That older description was arrived at without chemistry, and it does not map neatly onto constituent names — but it records centuries of observation about dose, preparation and who the plant suited.
The research base is developing: there are human trials, though sample sizes and designs vary, and this profile cites 2 sources. Reported findings centre on Multiple RCTs support Boswellia serrata extract (300-400mg TID) for OA. Where research exists, it examines boswellic acids inhibit 5-LOX — anti-inflammatory, may reduce osteoarthritis pain in RCTs and potential anti-tumor activity in preclinical models. These are areas of study, not established outcomes, and results differ by preparation and dose.
How the plant is prepared changes what you actually get. Its constituents move readily into fixed oil and alcohol — so a preparation made in another medium will not carry the same fraction of the plant, which is why traditional recipes specify one over another.
The reason Frankincense is treated as its own entry rather than a substitute for a related plant is proportion: related species share several of these compound classes, but not in the same ratio or concentration.
Because these constituents are processed by the same pathways that handle many medicines, Frankincense is documented as interacting with nsaids and anticoagulants. That is a question of shared metabolism rather than of potency, and it is the main reason the plant is listed in interaction references at all.
Dose, plant part and growing conditions all shift the constituent profile, so two products carrying the name Frankincense can differ substantially; this is why reference entries specify resin (oleogum) and, where they exist, standardisation markers.